
Derazantinib Shows Clinical Benefit, Manageable Safety Profile in Patients With Cholangiocarcinoma
Derazantinib is an investigational oral inhibitor of FGFR1, FGFR2, and FGFR3 in patients with locally advanced or metastatic intrahepatic cholangiocarcinoma.





























